BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives $137.86 Consensus PT from Analysts

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eighteen analysts that are presently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $137.91.

A number of analysts recently weighed in on the stock. Morgan Stanley set a $133.00 target price on shares of BioNTech and gave the company an "overweight" rating in a research note on Thursday. Citigroup reaffirmed a "buy" rating and set a $140.00 price objective (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. HC Wainwright reaffirmed a "buy" rating and set a $138.00 price objective on shares of BioNTech in a research note on Wednesday, June 25th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd.

Hedge Funds Weigh In On BioNTech

Several large investors have recently bought and sold shares of BNTX. FMR LLC lifted its holdings in BioNTech by 22.2% in the fourth quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after buying an additional 1,401,547 shares during the period. Bank of New York Mellon Corp raised its holdings in BioNTech by 18,892.9% in the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after purchasing an additional 694,691 shares during the period. BNP Paribas Financial Markets acquired a new stake in BioNTech in the fourth quarter worth $69,999,000. Invesco Ltd. increased its position in shares of BioNTech by 643.7% during the first quarter. Invesco Ltd. now owns 645,142 shares of the company's stock worth $58,747,000 after acquiring an additional 558,389 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of BioNTech by 632.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock worth $57,191,000 after acquiring an additional 433,388 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Price Performance

NASDAQ BNTX traded down $1.03 on Thursday, reaching $112.89. The company's stock had a trading volume of 521,908 shares, compared to its average volume of 943,543. The firm has a market cap of $27.14 billion, a PE ratio of -33.20 and a beta of 1.29. The business has a 50-day moving average price of $103.56 and a 200 day moving average price of $106.81. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.